Finance & Acquisitions: Replimune

Replimune's fiscal Q4 2025 earnings call, where the company provided updates on their lead product candidate RP1, an oncolytic immunotherapy for melanoma.

Key Highlights

Regulatory Progress

RP1 received breakthrough therapy designation and priority review

PDUFA (FDA approval decision) date is July 22, 2025

Recently completed late-cycle FDA meeting and manufacturing inspections

Company believes there are no impediments to approval

Clinical Data

The IGNITE study showed approximately one-third of patients achieved durable responses in anti-PD-1 failed melanoma

Median duration of response exceeded 20 months

Over 55% of patients still alive at 3 years

Confirmatory IGNITE 3 Phase III trial is underway with 400 patients across 100+ sites globally

Commercial Readiness

Built customer-facing team of ~60 people

Identified 350 key accounts treating about half of melanoma patients

Estimate ~13,000 patients progress on PD-1 treatment annually in the US, with 80% eligible for RP1

Unique approach requires collaboration between oncologists and interventional radiologists for deep lesion injections

Manufacturing facility ready with commercial inventory

Financial Position

$483.8 million in cash as of March 31, 2025

Cash runway extends into Q4 2026

Net loss of $247.3 million for fiscal year 2025

Upcoming Events

Investor Day planned for June 24, 2025

Data presentations at ASCO on systemic/visceral activity and safety

The company is positioning RP1 as a first-choice treatment for advanced melanoma patients who have failed anti-PD-1 therapy, emphasizing its differentiated mechanism, safety profile, and potential for broad adoption.RetryClaude can make mistakes. Please double-check responses. Sonnet 4Chat controls Sonnet 4